Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from enGene Holdings ( (ENGN) ).
enGene Holdings Inc. will showcase its non-viral genetic medicine platform and lead bladder cancer program as President and CEO Ron Cooper participates in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, with the session streamed live and archived via the company’s investor website. The appearance underscores enGene’s effort to raise its profile among biotech investors and highlight the clinical progress of its Phase 2 LEGEND trial for detalimogene voraplasmid in high-risk Non-Muscle Invasive Bladder Cancer, potentially strengthening its positioning in the genetic medicines space and drawing attention to its DDX platform for delivering DNA and RNA therapies to mucosal tissues.
The most recent analyst rating on (ENGN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.
Spark’s Take on ENGN Stock
According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.
The score is held down primarily by weak financial performance (no revenue, large operating losses, and significant cash burn). Technicals are supportive due to a strong uptrend, but momentum appears overextended. The recent $130M financing improves funding runway, partially offsetting the weak fundamentals, while valuation remains constrained by a negative P/E and no dividend support.
To see Spark’s full report on ENGN stock, click here.
More about enGene Holdings
enGene Holdings Inc. is a clinical-stage biotechnology company developing non-viral genetic medicines, focusing on delivering therapeutics to mucosal tissues and other organs to address diseases with high unmet clinical needs. Its lead program, detalimogene voraplasmid (detalimogene, formerly EG-70), targets Non-Muscle Invasive Bladder Cancer and is being evaluated in the multi-cohort LEGEND Phase 2 trial, including a pivotal cohort in high-risk, BCG-unresponsive patients with carcinoma in situ, and is built on the company’s proprietary Dually Derivatized Oligochitosan (DDX) delivery platform.
Average Trading Volume: 1,307,197
Technical Sentiment Signal: Buy
Current Market Cap: $669.8M
For detailed information about ENGN stock, go to TipRanks’ Stock Analysis page.